Oncology · HER2-positive Breast CancerRegulatory Approvalregulatorymid-term

FDA Submission Update for ONTRUZANT (BLA761100) by Samsung Bioepis

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/26/2026, 6:32:31 PM

Assessment confidence: 72% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's receipt of a supplemental application for ONTRUZANT signals an important development in the competitive landscape of HER2-targeting biosimilars. This could affect pricing strategies and market dynamics for existing trastuzumab products, necessitating close monitoring by portfolio teams. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 2 ranked evidence items (1 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this submission on existing trastuzumab products and pricing strategies. The strongest clinical anchor is An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov), sub-indication match (her2); mechanism alignment (her2). In her2, 1 regulatory and 0 competitive items passed relevance filtering for ONTRUZANT.

Competitive Pressure

The most relevant competitive pressure comes from This submission indicates ongoing competition in the biosimilar market for trastuzumab, potentially impacting pricing and market share..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONTRUZANT (SUPPL) (FDA). Entity match (ontruzant); Regulatory pathway relevance (bla). The submission indicates a significant regulatory event that could lead to changes in market access and compliance requirements for biosimilars in oncology.

Key Risks

Elevated medium regulatory exposure for ONTRUZANT could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval of ONTRUZANT could lead to increased competition, potentially driving down prices and impacting market share for current trastuzumab products.
Upside for ONTRUZANT may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the implications of this submission on existing trastuzumab products and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONTRUZANT (SUPPL)
FDAmedium relevance
Entity match (ontruzant); Regulatory pathway relevance (bla)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Other | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View source
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

No evidence in this category.

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ONTRUZANT

Commercial impact

medium

The approval of ONTRUZANT could lead to increased competition, potentially driving down prices and impacting market share for current trastuzumab products.

Regulatory impact